Page 345 of 449: studies 3,441 to 3,450 of 4,486, newest first. Back to the ketamine overview
March 1, 2020 Adam Winstock, James W. Rucker 29 citations
Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...
bioRxiv (Cold Spring Harbor Laboratory) January 23, 2020 Ca Hales, Jm Bartlett, Roberto Arban et al. preprint
Abstract Major Depressive Disorder is a significant and costly cause of global disability. Until the discovery of the rapid acting antidepressant (RAAD) effects of ketamine, treatments were limited to drugs that have delayed clinical benefits. The mechanism of action of ketamine is currently unclear but one hypothesis is that it may involve neuropsychological effects mediated through modulation...
Absolute Addiction Psychiatry Review 2020 Mashal Khan, Anil A. Thomas 3 citations
Anabolic-androgenic steroids, inhalants, hallucinogens, dissociative anesthetics and “club drugs” are a heterogeneous group of substances that have considerable potential for misuse and associated morbidity and/or mortality. Steroid use often goes undetected, even by addiction psychiatrists, though significant medical and psychiatric consequences often arise from chronic use. Inhalants, which...
European Journal of Pharmacology August 15, 2019 Jason Wallach, Tristan Colestock, Julià Agramunt et al.
1,2-Diarylethylamines represent a class of molecules that have shown potential in the treatment of pain, epilepsy, neurodegenerative disease and depression. Examples include lefetamine, remacemide, and lanicemine. Recently, several 1,2-diarylethylamines including the dissociatives diphenidine, methoxphenidine and ephenidine as well as the opioid MT-45, have appeared as 'research chemicals' or...
Journal of Molecular Neuroscience July 2019 Cheng Jiang, Wei-Jye Lin, Stephen R Salton
Members of the neurotrophin family and in particular brain-derived neurotrophic factor (BDNF) regulate the response to rapid- and slow-acting chemical antidepressants and voluntary exercise. Recent work suggests that rapid-acting antidepressants that modulate N-methyl-D-aspartate receptor (NMDA-R) signaling (e.g., ketamine and GLYX-13) require expression of VGF (non-acronymic), the...
Molecular Neurobiology June 1, 2019 Samuel Kohtala, Wiebke Theilmann, Marko Rosenholm et al.
Rapid antidepressant effects of ketamine become most evident when its psychotomimetic effects subside, but the neurobiological basis of this "lag" remains unclear. Laughing gas (N2O), another NMDA-R (N-methyl-D-aspartate receptor) blocker, has been reported to bring antidepressant effects rapidly upon drug discontinuation. We took advantage of the exceptional pharmacokinetic properties of N2O...
JAMA May 24, 2019 Ole Köhler‐forsberg, Cristina Cusin, Andrew A. Nierenberg 18 citations
This Viewpoint discusses recent evidence documenting benefits of nonpharmacological and drug therapies for major depressive disorder including exercise, Mediterranean diet and structured dietary support, ketamine and esketamine, anti-inflammatory drugs, brexanolone, and psilocybin.
The FASEB Journal April 1, 2019 Meghan Hibicke, Alexus N. Landry, Zoe K. Talman et al. 7 citations
Introduction Psilocybin has recently demonstrated profound efficacy to alleviate depression and anxiety in several clinical trials and has received Breakthrough Status by the FDA. Symptomatic relief after only one or two therapeutic treatments last for at least several months in the vast majority of individuals. It is unclear whether the persistent antidepressant and anxiolytic effects are a...
bioRxiv (Cold Spring Harbor Laboratory) March 9, 2019 Andria Pelentritou, Levin Kuhlmann, John Cormack et al. 1 citation preprint
B. Abstract Background. Despite their intriguing nature, investigations of the neurophysiology of N-methyl-D-aspartate (NMDA)-antagonists Xenon (Xe) and nitrous oxide (N 2 O) are limited and have revealed inconsistent frequency-dependent alterations, in spectral power and functional connectivity. Discrepancies are likely due to using low resolution electroencephalography restricted to sensor...
Journal of Neuroscience Research March 2019 Ronald S. Duman, Matthew J. Girgenti
The neurobiology of fear memory and extinction has been the subject of extensive research efforts that have increased our understanding of the brain regions, circuitry, and the cellular and molecular determinants of fear memory processes. However, the inability to access and directly study the brains of PTSD patients has made it difficult to translate the rodent fear memory studies to...